France Innovation Scientifique & Transfert Publishes a New Report on the HIV Therapy Patent Landscape. This Report Shows a Drastic Need for Fundamental Research.

PARIS--(Business Wire)--
"IP Overview HIV Therapy 2009" (
www.frinnov.fr/en/ip-overview/sciences-de-la-vie/hiv-therapy-2.html )
establishes a panorama of the patents claiming "HIV and AIDS treatments" and
analyses the key and emerging thematic and the strategic positions of the actors
involved in this sector. In order to fully analyze this field, the information
coming from 6800 published patents and patent applications was aggregated.

Highlights of this report

This analysis shows a decorrelation between major patent owners and market
leaders. Companies having the largest patent portfolio claiming HIV treatments,
Pfizer and Merck (350 patents fillings, each) do not belong to the HIV market
leaders while Gilead with only 44 patent filings has the best market results.
This position is therefore not a result of internal research but is based on the
acquisition of key molecules such as emtricitabine coming from a collaboration
between IOCB and Leuven Katholic University and tenofovir from Emory University.

In addition, according to Sylvain Goiran, IP Overview principal analyst:
"Despite the huge increase in HIV market and the needs for new therapies,
multiple signals are showing that HIV R&D is running short of new thematic and
is practically collapsing since 2005 with a 40% drop in the number of patent
applications". Fewer filings means fewer new molecules entering clinical trials
and thus fewer chances for new drugs on the market in the future. There is
undoubtedly a need to get back to basic research. It is therefore a unique
opportunity for academic research to play a crucial role in this field in the
coming years.

Indeed, like Gilead, pharmaceutical companies could adapt their strategies and
go for "open innovation" by buying or licensing active molecules from academic
laboratories or other companies.

So, a deep knowledge of the patent portfolio of HIV therapy can help companies
to identify players that patented molecules acting on new therapeutic targets.

Key reasons to purchase this report:

This report provides a comprehensive analysis of why the R&D of HIV treatments
is at a crossroads, as can be seen on the patent perspective. It gives detailed
information about some of the key aspects of the pharmaceutical industry and
helps clients to identify the driving forces and current trends in this field.
"This represents a fully new approach which is complementary with classical
market studies." concludes Sylvain Goiran.

For more information visit
www.frinnov.fr/en/ip-overview/sciences-de-la-vie/hiv-therapy-2.html

Key items

* Outline of the market and the pipeline
* Protection strategies:

* Evolution of patent filings
* Priority patent applications
* Extensions
* Analysis of industrial patents over time
* Study of the granting of US and European patents

* Topology of patents in the sector

* Breakdown of patents into therapeutic targets, applications, class of
compounds and cross-analyses

* Keys applicants and key inventors
* Key and emerging thematic
* Conclusion

Sylvain Goiran
IP Overview Principal Analyst
sylvain.goiran@fist.fr
+33 (0)140 510 090

Copyright Business Wire 2009